Compare Incyte Corporation (INCY) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Teucrium Wheat Fund — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Teucrium Wheat Fund trades at $25.21. Which is the better fit depends on your goals.
| INCY | WEAT | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $118.52 | $25.49 |
52-Week Low | $67.38 | $19.88 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
WEAT trades at $24.99, down 1.03% in the last session, with technical indicators showing a mixed but overall bullish bias. The USDA's reduced 2026 wheat production forecast to 1.56 billion bushels (WSJ, 2026-05-12) and recent wheat price volatility highlight fundamental supply-side influences. Moving averages signal strong bullish momentum, though oscillators indicate near-term overbought conditions.
The outlook for WEAT is cautiously optimistic, driven by agricultural commodity trends and supportive technicals. Key opportunities include exposure to wheat price appreciation, but risks involve weather impacts on crops, inflation fluctuations, and competitive ETF pressure as noted in recent coverage (24/7 Wall Street, 2026-05-16).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
